FranÃ§ois Mouton-Liger

List of Publications by Year
in descending order

25 papers	1,051 citations	430874 18 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	1624 citing authors

#	Article	IF	Citations
1	Plasma neuregulin 1 as a synaptic biomarker in Alzheimerâ€™s disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	6.2	12
2	Ketogenic diet therapy in Alzheimer's disease: an updated review. Current Opinion in Clinical Nutrition and Metabolic Care, 2021, 24, 372-378.	2.5	22
3	Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. Frontiers in Nutrition, 2021, 8, 807970.	3.7	17
4	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 88.	6.2	20
5	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. Immunology Letters, 2020, 228, 129-134.	2.5	38
6	Are ketogenic diets promising for Alzheimerâ€™s disease? A translational review. Alzheimer's Research and Therapy, 2020, 12, 42.	6.2	38
7	<scp>P</scp>arkin deficiency modulates <scp>NLRP</scp>3 inflammasome activation by attenuating an <scp>A</scp>20â€dependent negative feedback loop. Glia, 2018, 66, 1736-1751.	4.9	100
8	PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease. Frontiers in Molecular Neuroscience, 2017, 10, 120.	2.9	75
9	Neuroinflammation and AÎ² Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. Scientific Reports, 2015, 5, 8489.	3.3	70
10	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. Journal of Psychiatry and Neuroscience, 2015, 40, 151-161.	2.4	75
11	Effect of active AÎ² immunotherapy on neurons in human Alzheimer's disease. Journal of Pathology, 2015, 235, 721-730.	4.5	31
12	Impact of cerebro-spinal fluid biomarkers of Alzheimerâ€™s disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	3.6	56
13	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. Journal of Alzheimer's Disease, 2014, 40, 857-861.	2.6	22
14	The screening of Alzheimerâ€™s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	3.6	11
15	Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: Implications for Down syndrome. Neurobiology of Disease, 2014, 63, 92-106.	4.4	17
16	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e53587.	2.5	46
17	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2Î± pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 885-896.	3.8	139
18	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52

#	Article	IF	Citations
19	The PKR Activator PACT Is Induced by AÎ²: Involvement in Alzheimer's Disease. Brain Pathology, 2012, 22, 219-229.	4.1	40
20	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. Brain Pathology, 2011, 21, 189-200.	4.1	55
21	Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH-SY5Y cells. FEBS Letters, 2011, 585, 1801-1806.	2.8	24
22	CSF AÎ²1-42 Levels and Glucose Metabolism in Alzheimer's Disease>. Journal of Alzheimer's Disease, 2011, 27, 845-851.	2.6	20
23	PCP4 (PEP19) overexpression induces premature neuronal differentiation associated with Ca²⁺/CalmodulinâĐependent kinase IIâĚŕ activation in mouse models of down syndrome. Journal of Comparative Neurology, 2011, 519, 2779-2802.	1.6	39
24	Biogenesis and regulation of microRNA: implication in Alzheimerâ€™s disease. Future Neurology, 2010, 5, 839-850.	0.5	2
25	Inverse association between CSF AÎ² 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. Neurobiology of Disease, 2010, 40, 456-459.	4.4	30